Xencor (NASDAQ:XNCR) Sets New 12-Month High – What’s Next?

Xencor, Inc. (NASDAQ:XNCR)’s share price reached a new 52-week high during trading on Tuesday . The company traded as high as $20.26 and last traded at $18.81, with a volume of 2862329 shares changing hands. The stock had previously closed at $17.47.

Analyst Upgrades and Downgrades

Several equities research analysts have commented on the stock. Truist Financial decreased their target price on shares of Xencor from $29.00 to $27.00 and set a “buy” rating on the stock in a research report on Tuesday, July 7th. Zacks Research upgraded shares of Xencor from a “strong sell” rating to a “hold” rating in a research note on Monday, July 6th. Weiss Ratings reissued a “sell (d-)” rating on shares of Xencor in a report on Wednesday, June 24th. JPMorgan Chase & Co. upped their target price on shares of Xencor from $13.00 to $14.00 and gave the stock a “neutral” rating in a research report on Monday, May 11th. Finally, Wall Street Zen cut shares of Xencor from a “hold” rating to a “strong sell” rating in a report on Saturday, May 9th. Six research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Xencor presently has an average rating of “Moderate Buy” and a consensus target price of $24.25.

Xencor Stock Down 4.6%

The company has a market cap of $1.45 billion, a price-to-earnings ratio of -8.52 and a beta of 0.86. The company has a fifty day simple moving average of $13.63 and a two-hundred day simple moving average of $12.87.

Xencor (NASDAQ:XNCR) last released its quarterly earnings results on Wednesday, May 6th. The biopharmaceutical company reported ($1.71) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.75) by ($0.96). Xencor had a negative return on equity of 28.77% and a negative net margin of 177.10%.The firm had revenue of $4.52 million for the quarter, compared to analyst estimates of $27.86 million. During the same period last year, the firm earned ($0.66) EPS. The company’s quarterly revenue was down 86.2% compared to the same quarter last year. On average, research analysts predict that Xencor, Inc. will post -3.88 EPS for the current year.

Institutional Trading of Xencor

Several institutional investors and hedge funds have recently modified their holdings of XNCR. Jefferies Financial Group Inc. grew its holdings in Xencor by 620.4% during the 4th quarter. Jefferies Financial Group Inc. now owns 720,440 shares of the biopharmaceutical company’s stock valued at $11,030,000 after buying an additional 620,440 shares during the last quarter. Vanguard Group Inc. raised its holdings in shares of Xencor by 0.9% in the fourth quarter. Vanguard Group Inc. now owns 7,165,450 shares of the biopharmaceutical company’s stock worth $109,703,000 after acquiring an additional 61,692 shares during the last quarter. Erste Asset Management GmbH raised its holdings in shares of Xencor by 26.3% in the fourth quarter. Erste Asset Management GmbH now owns 480,200 shares of the biopharmaceutical company’s stock worth $7,347,000 after acquiring an additional 100,000 shares during the last quarter. BVF Inc. IL lifted its position in shares of Xencor by 160.3% in the fourth quarter. BVF Inc. IL now owns 7,133,720 shares of the biopharmaceutical company’s stock valued at $109,217,000 after acquiring an additional 4,393,579 shares in the last quarter. Finally, JPMorgan Chase & Co. lifted its position in shares of Xencor by 21.7% in the third quarter. JPMorgan Chase & Co. now owns 401,501 shares of the biopharmaceutical company’s stock valued at $4,710,000 after acquiring an additional 71,494 shares in the last quarter.

About Xencor

Xencor, Inc is a clinical-stage biopharmaceutical company focused on the design and development of engineered protein therapeutics for the treatment of autoimmune diseases, cancer and neurological disorders. The company applies its proprietary XmAb® platform to manipulate antibody structure and function, creating molecules with enhanced immune engagement and extended half-life. Xencor’s research programs span a range of therapeutic modalities, including monoclonal antibodies, bispecific antibodies and cytokine-based fusion proteins.

The XmAb® platform enables precise modification of the Fc region to augment key properties such as receptor binding, effector function and pharmacokinetics.